Menu
Menu
What if the biggest risk from AI isn't that machines outsmart us — but that we stop thinking for ourselves?
In this episode of Decoded, Dr. Jurgi Camblong sits down with Joseph Sifakis, Turing Award winner (aka "the Nobel Prize of computer science"), to challenge some of the most common myths about artificial intelligence — and to name the risk he believes we're ignoring.
Joseph invented model checking, the science that proves automated systems do what they're supposed to do. From Intel to NASA to Google, his work underpins how the world verifies critical technology today. Few people are better positioned to separate real AI risk from AI hype.
You'll hear:
A rigorous, clear-eyed conversation on AI, human cognition, and what we risk losing if we stop thinking for ourselves.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
